Association between variants A69S in ARMS2 gene and response to treatment of exudative AMD: A meta-analysis

British Journal of Ophthalmology

Volumn 99, Issue 5, 2015, Pages 593-598

  Hu, Zizhong ^a   Xie, Ping ^a   Ding, Yuzhi ^a   Yuan, Dongqing ^a   Liu, Qinghuai ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; RANIBIZUMAB; ARMS2 PROTEIN, HUMAN; PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; ALLELE; ANTIANGIOGENIC THERAPY; ARMS2 GENE; BIOINFORMATICS; CAUCASIAN; DATA ANALYSIS; DATA ANALYSIS SOFTWARE; EAST ASIAN; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERVENTION STUDY; META ANALYSIS; PHOTODYNAMIC THERAPY; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; TREATMENT RESPONSE; WET MACULAR DEGENERATION; ANTAGONISTS AND INHIBITORS; GENETICS;

ANGIOGENESIS INHIBITORS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84928193976     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-305488     Document Type: Review

References (46)

1. De Jong PT. Age-related macular degeneration. N Engl J Med 2006;355:1474-85.
2. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2.
3. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72.
4. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2010;117:921-7.
5. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study report number 3. Ophthalmology 2000;107:2224-32.
6. Mullins RF. Genetic insights into the pathobiology of age-related macular degeneration. Int Ophthalmol Clin 2007;47:1-14.
7. Swaroop A, Chew EY, Rickman CB, et al. Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet 2009;10:19-43.
8. Rivera A, Fisher SA, Fritsche LG, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 2005;14:3227-36.
9. Kortvely E, Hauck SM, Duetsch G, et al. ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations. Invest Ophthalmol Vis Sci 2010;51:79-88.
10. Kanda A, Chen W, Othman M, et al. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci USA 2007;104:16227-32.
11. Fritsche LG, Loenhardt T, Janssen A, et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet 2008;40:892-6.
12. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
13. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
14. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72.
15. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48.
16. Schmidt-Erfurth U, Miller J W, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 1999;117:1177-87.
17. McKibbin M, Ali M, Bansal S, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 2012;96:208-12.
18. Klein ML, Francis PJ, Rosner B, et al. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 2008;115:1019-25.
19. Kang HK, Yoon MH, Lee DH, et al. Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population. Korean J Ophthalmol 2012;26:414-22.
20. dos Reis Veloso CE, Frota de Almeida LN, Recchia FM, et al. VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration. Ophthalmic Res 2013;51:1-8.
21. Smailhodzic D, Muether PS, Chen J, et al. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology 2012;119:2304-11.
22. Nischler C, Oberkofler H, Ortner C, et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol 2011;89:e344-49.
23. Chen H, Yu KD, Xu GZ. Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis. PloS ONE 2012;7:e42464.
24. Bessho H, Honda S, Kondo N, et al. The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Mol Vis 2011;17:977-82.
25. Inglehearn CF, Ali M, Gale R, et al. Improved response to ranibizumab in ex and current smokers with age-related macular degeneration (AMD), but no evidence that CFH, ARMS2/HTRA1 Or VEGF genotypes predict treatment outcome. Invest Ophthalmol Vis Sci 2012;53:3325.
26. Kloeckener-Gruissem B, Barthelmes D, Labs S, et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 2011;52:4694-702.
27. Teper SJ, Nowinska A, Pilat J, et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis 2010;16:2598-604.
28. Yu KD, Shao ZM. Inspection of a deviation from Hardy-Weinberg equilibrium in familial breast cancer cases from a case-control study in a meta-analysis. Breast Cancer Res Treat 2001;127:577-9.
29. Brantley MA Jr, Fang AM, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007;114:2168-73.
30. Orlin A, Hadley D, Chang W, et al. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 2012;32:4-9.
31. Hagstrom SA, Ying GS, Pauer GJ, et al. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 2013;120:593-9.
32. Hautamäki A, Kivioja J, Vavuli S, et al. Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration. Retina 2013;33:1815-27.
33. Kitchens JW, Kassem N, Wood W, et al. A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration. Clin Ophthalmol 2013;7:1987-93.
34. Lotery AJ, Gibson J, Cree AJ, et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study. Ophthalmology 2013;120:2637-43.
35. Abedi F, Wickremasinghe S, Richardson AJ, et al. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Ophthalmology 2013;120:1641-8.
36. Yamashiro K, Tomita K, Tsujikawa A, et al. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am J Ophthalmol 2012;154:125-36.
37. Fang K, Tian J, Qing X, et al. Predictors of visual response to intravitreal bevacizumab for treatment of neovascular age-related macular degeneration. J Ophthalmol 2013;2013:676049.
38. Park DH, Kim IT. LOC387715-HTRA1 variants and the response to combined photodynamic therapy with intravitreal bevacizumab for polypoidal choroidal vasculopathy. Retina 2012;32:299-307.
39. Matsumiya W, Honda S, Yanagisawa S, et al. Evaluation of clinical and genetic indicators for the early response to intravitreal ranibizumab in exudative age-related macular degeneration. Pharmacogenomics 2014;15:833-43.
40. Park UC, Shin JY, Kim SJ, et al. Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration. Retina 2014;34:288-97.
41. Kondo N, Honda S, Ishibashi K, et al. LOC387715/HTRA1 variants in polypoidal choroidal vasculopathy and age-related macular degeneration in a Japanese population. Am J Ophthalmol 2007;144:608-12.
42. Gotoh N, Nakanishi H, Hayashi H, et al. ARMS2 (LOC387715) variants in Japanese patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Am J Ophthalmol 2009;147:1037-41.
43. Jakobsdottir J, Conley YP, Weeks DE, et al. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet 2005;77:389-407.
44. Cheng Y, Huang L, Li X, et al. Genetic and functional dissection of ARMS2 in age-related macular degeneration and polypoidal choroidal vasculopathy. PLoS ONE 2013;8:e53665.
45. Yuan D, Yuan D, Yuan S, et al. The age-related maculopathy susceptibility 2 polymorphism and polypoidal choroidal vasculopathy in Asian populations: a meta-analysis. Ophthalmology 2013;120:2051-7.
46. Wang G, Spencer KL, Scott WK, et al. Analysis of the indel at the ARMS2 3′UTR in age-related macular degeneration. Hum Genet 2010;127:595-602.